Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
|
|
- Paula Cannon
- 6 years ago
- Views:
Transcription
1 University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2009 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide Glas, M; Happold, C; Rieger, J; Wiewrodt, D; Bähr, O; Steinbach, J P; Wick, W; Kortmann, R; Reifenberger, G; Weller, M; Herrlinger, U Glas, M; Happold, C; Rieger, J; Wiewrodt, D; Bähr, O; Steinbach, J P; Wick, W; Kortmann, R; Reifenberger, G; Weller, M; Herrlinger, U (2009). Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide. Journal of Clinical Oncology, 27(8): Postprint available at: Posted at the Zurich Open Repository and Archive, University of Zurich. Originally published at: Journal of Clinical Oncology 2009, 27(8):
2 JCO/2008/ Glas et al. 1 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide Martin Glas 1*, Caroline Happold 2,3*, Johannes Rieger 2,4, Dorothee Wiewrodt 5, Oliver Bähr 2,4, Joachim P. Steinbach 2,4, Wolfgang Wick 2,6, Rolf-Dieter Kortmann 7, Guido Reifenberger 8, Michael Weller 2,3, Ulrich Herrlinger 1,2 1 Division of Clinical Neurooncology, Department of Neurology, University of Bonn, Sigmund-Freud-Str. 25, D Bonn, Germany, Tel.: , Fax: Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Str. 3, D Tübingen, Germany, Tel.: , Fax: Department of Neurology, University Hospital Zürich, Frauenklinikstrasse 26, CH-8091 Zürich, Switzerland, Tel.: , Fax: Dr. Senckenbergisches Institut of Neurooncology, University of Frankfurt, Schleusenweg 2-16, D Frankfurt am Main, Germany, Tel.: , Fax: Department of Neurosurgery, University of Mainz, Langenbeckstr. 1, D Mainz, Germany, Tel , Fax: Department of Neurooncology, University of Heidelberg, Germany, Im Neuenheimer Feld 400, Heidelberg, Germany, Tel.: , Fax: Department of Radiation Oncology, University of Leipzig, Stephanstrasse 9a, D Leipzig, Germany, Tel.: , Fax: Department of Neuropathology, Heinrich-Heine-University of Duesseldorf, Moorenstr. 5, D Düsseldorf, Germany, Tel , Fax * Authors contributed equally to this work. Running head: Long-term survival after lomustine plus temozolomide therapy of glioblastoma This manuscript contains only original material and has not been published elsewhere. Address for correspondence: Ulrich Herrlinger, MD, Division of Clinical Neurooncology, Department of Neurology, University of Bonn, Sigmund-Freud-Str. 25, D Bonn, Germany, Tel.: , Fax: , Ulrich.Herrlinger@ukb.uni-bonn.de Abstract
3 JCO/2008/ Glas et al. 2 Purpose: To evaluate long-term survival in a prospective series of newly diagnosed glioblastoma patients treated with a combination of lomustine (CCNU), temozolomide (TMZ) and radiotherapy. Patients and methods: Thirty-nine patients received radiotherapy of tumor site only (60 Gy) and CCNU/TMZ chemotherapy (n=31 with standard dose CCNU 100 mg/m 2 (day 1), TMZ 100 mg/m 2 /d (day 2 to 6); n=8 with intensified dose CCNU 110 mg/m 2 (day 1), TMZ 150 mg/m 2 (day 2 to 6)) for up to 6 courses. Results: In the whole cohort, the median overall survival (mos) was 23.1 months with 47.4% surviving for 2 years and 18.5% for 4 years. After a median follow-up of 41.5 months, mos has not been reached in the intensified group and is significantly higher than in the standard group (22.6 months; p=0.024). In the intensified group, 4 of 8 patients survive for at least 56 months, two of them without recurrence. O6- methylguanine-dna methyltransferase (MGMT) gene promotor methylation in the tumor tissue was associated with a significantly longer mos (methylated 34.3 months vs. non-methylated 12.5 months). A multivariate Cox proportional hazard model revealed MGMT status (methylated vs. non-methylated, relative risk (RR) of death 0.43, p=0.003) and chemotherapy dose (intensified vs. standard, RR 0.37, p=0.012) as independent prognostic factors. WHO grade 4 hematoxicity was observed more frequently in the intensified group (57% vs. 16%). Conclusion: The combination of radiotherapy, CCNU and TMZ yielded promising long-term survival data in newly diagnosed glioblastoma. Intensification of CCNU/TMZ chemotherapy may add an additional survival benefit albeit with higher acute toxicity.
4 JCO/2008/ Glas et al. 3 Introduction Despite recent improvements in surgery and combined radiochemotherapy, glioblastoma remains a devastating disease. Standard radiochemotherapy includes concomitant and adjuvant temozolomide (TMZ) chemotherapy and leads to a median progression-free survival (mpfs) of 6.9 months and a median overall survival time (mos) of 14.6 months. 1 Using a combination of TMZ and lomustine (CCNU) in the UKT-03 trial, we have previously reported promising survival data with a mpfs of 9 months and a high mos of 22.6 months. 2 Thirteen of 31 patients in the UKT-03 trial were alive at the end of the 24 months follow-up period reported in the previous publication. 2 In our present analysis carried out 55 months after the accrual of the last patient to the trial, we report mature data on long-term survival in the UKT-03 cohort. Furthermore, we added the previously unpublished data set of a pilot group of 8 patients treated with an intensified CCNU/TMZ regimen that might confer even higher rates of long-term survival. Overall, we report on the long-term survival of 39 prospectively documented patients receiving radiotherapy and combined CCNU/TMZ chemotherapy as first-line therapy for glioblastoma.
5 JCO/2008/ Glas et al. 4 Patients and methods This prospective series of patients treated with CCNU and TMZ includes 31 patients treated in the UKT-03 trial 2 and 8 patients treated in a prospective pilot group with increased CCNU and TMZ doses. All patients received treatment at the University of Tuebingen (Dept. of Neurology, Tuebingen, Germany) and Mainz (Dept. of Neurology and Neurosurgery, Mainz, Germany) Medical Centers. The main inclusion criteria for both groups were histological diagnosis of glioblastoma, surgery no longer than 21 days before, no prior radiotherapy or chemotherapy, age older than 18 years, Karnofsky performance score (KPS) of 70% or higher, and no alterations in bone marrow reserve, liver function, or renal function. Both treatment regimens were approved by the local Ethics Committees. All patients gave written informed consent. In all patients, the therapy-independent prognostic factors KPS at entry into the study and the extent of resection as determined by the neurosurgeon were defined. Furthermore, the study population was assigned to one of the prognostic groups developed by recursive partitioning analysis 3 and validated in a large number of glioma patients enrolled in Radiation Therap Oncology Group trials. 4 The chemotherapy schedule included oral CCNU 100 mg/m 2 on day 1 followed by TMZ 100 mg/m 2 /d on days 2-6 of 6-week courses ( standard group ). The patients of the pilot cohort received a dose intensification with CCNU 110 mg/m 2 on day 1 followed by TMZ 150 mg/m 2 /d on days 2-6 ( intensified group ). A maximum of 6 courses were delivered with individual dose adjustments in subsequent courses and discontinuation rules as previously described. 2 Radiotherapy was delivered during courses 1 and 2 as involved-field radiotherapy with a total dose of 60 Gy in single daily fractions of 2 Gy. Toxicity of the CCNU/TMZ treatment regimen was continously monitored throughout the treatment and follow-up phase in the whole cohort. O 6 -
6 JCO/2008/ Glas et al. 5 methylguanine methyltransferase (MGMT) promoter methylation status was analyzed in all available samples by methylation-specific PCR as previously described. 2, 5 Response assessment was based on contrast-enhanced MRI after courses 2, 4, and 6. 6 After chemotherapy, patients were followed at 3 months intervals by clinical examination and contrast-enhanced MRI. All patients were assessed for progressionfree survival upon CCNU/TMZ and subsequent therapies, overall survival and late toxicity. PFS and OS were calculated from the day of surgery leading to the histologic diagnosis of GBM. Second PFS were calculated from the day of diagnosis of recurrence on MRI. Survival data were analyzed according to the Kaplan-Meier method using the logrank test for comparisons between different groups. Also, the influence of the MGMT promoter methylation status (methylated vs. non-methylated), CCNU/TMZ dosing (intensified vs. standard), extent of resection (complete vs. incomplete resection or biopsy) and RTOG RPA class (class III vs. class IV or V) was analyzed in univariate regression analyses using a Cox proportional hazards model. Parameters with a significant influence on survival in the univariate analysis were also analyzed in a multivariate analysis.
7 JCO/2008/ Glas et al. 6 Results Patient characteristics and therapy applied Thirty-nine patients were accrued between March 2002 and December Thirtyone patients were treated in the UKT-03 trial ( standard group ) and 8 patients were treated with higher doses of CCNU and TMZ in an additional pilot group ( intensified group ). Patients characteristics are summarized in Table 1. The patients of the intensified group were older than the UKT-03 patients (median age 59 vs. 51 years) but did not differ with respect to KPS. The patients in the intensified group received a median of 3.5 courses CCNU/TMZ (range, 1-6 courses), patients of the UKT-03 group received a median of 4.5 courses (range, 1-6 courses). Twenty-seven patients (69%) received second-line therapy with a mpfs of 6 months. Eleven of 27 patients had an additional tumor resection at recurrence. Reirradiation was applied in 7 patients (mpfs 4 months) and hyperthermia in one patient. Second-line chemotherapy consisted of intensified TMZ in 10 patients (mpfs 7,5 months) and ACNU/VM26 in 8 patients (mpfs 3 months). Third-line (n=11, mpfs 4 months) and fourth-line therapy (n=3, mpfs 2 months) included reirradiation, intensified TMZ, ACNU, CCNU, pegylated liposomal doxorubicine and imatinib/hydroxyurea. Toxicity Acute toxicity was higher in the intensified cohort than in the standard group with grade 4 myelotoxicity occuring in 4 of 7 evaluable patients (57%) compared to 16% in the cohort of 31 patients treated with standard-dose CCNU/TMZ. As with the standard dose 2, one patient died from septicemia during myelosuppression. No nonhematological acute or delayed toxicity was observed.
8 JCO/2008/ Glas et al. 7 There were no signs of therapy-dependent late neurotoxicity in the long-term surviving patients. In all 3 patients who have survived without recurrent disease, the KPS months after inclusion into the trial has not decreased. Two of three patients who had one recurrence had a decrease of KPS, from 100% to 70% and from 80% to 50%, upon progression, but have remained on a stable KPS upon successful treatment of recurrence. One additional patient has remained on a stable KPS of 100% despite recurrence. In summary, decreases in KPS in some long-term survivors were attributable to recurrent disease, but not to CCNU/TMZ therapy. Long-term survival and dependency on MGMT promoter methylation status In the whole cohort of 39 patients, the mpfs was 10 months (range months). The mos was 23.1 months (Fig. 1). Overall survival was 47.4% at 2 years, 26.4% at 3 years, 18.5% at 4 years, and 15.8% at 5 years. Four of 39 patients (10.3%) have had no recurrence so far. Two of 8 patients in the intensified group (25%) have remained recurrence-free. Eight of 19 investigated patients in the standard group and 3 of 4 investigated patients of the intensified group had a methylated MGMT promotor. Survival strongly depended on the MGMT promoter methylation status. Median PFS (Fig. 2a) was significantly higher in the methylated group (19 months, n=11) than in the nonmethylated group (7 months, n=12) (p=0.0064). This also translated into a substantial overall survival benefit (Fig. 2b) for patients with a methylated MGMT promoter: median OS was 12.5 months for non-methylated patients, but 34.3 months for
9 JCO/2008/ Glas et al. 8 methylated patients (p=0.0009). In the methylated group, 45% of patients survived 3 years and 36% of patients survived 5 years. Influence of dose escalation on survival In the standard group, the mpfs was 9 months (range, 1.9 to 54+ months; Fig. 3a) and the mos was 22.6 months. 2 The long-term survival analysis now shows 41.9% of patients surviving 2 years, 16.9% of patients surviving 3 years and 9.7% surviving 4 years (Fig. 3b). In contrast, the 8 patients in the intensified group had a mpfs of 26 months and mos was not yet reached after a median follow-up time of 41.5 months (range, month). Both PFS (p=0.014) and OS (p=0.024) were significantly higher in the intensified group than in the standard group. Four of 8 patients in the intensified group are currently surviving for at least 56 months, 2 of them without any recurrence or signs of late neurotoxicity. Of the 4 patients in the intensified group which could be assessed for MGMT promoter status, the 3 patients with a methylated promoter are all still surviving after a follow-up time of months while the patient with a non-methylated MGMT promoter has died after 28 months. A univariate Cox proportional hazards analysis identified MGMT promoter methylation status and chemotherapy dose as factors which have an influence on survival (Table 2). In contrast, extent of resection and RTOG RPA class have no such effect. A subsequent multivariate analysis confirmed that the presence of a methylated MGMT promoter and the application of intensified CCNU/TMZ were associated with a significantly reduced risk of death (Table 2).
10 JCO/2008/ Glas et al. 9 Discussion The data presented here suggest that the combination of CCNU, TMZ, and radiotherapy has very encouraging activity in patients with newly diagnosed glioblastoma and may lead to a substantial rate of patients with long-term survival. The rate of long-term survivors >24 months is stunning with almost 50% in the whole cohort. This might be the best rate ever observed in a prospective glioblastoma analysis and does not appear to be bias-driven. 2 The fact that patients with a nonmethylated MGMT promoter in our trial survived only 12.5 months which is virtually identical to the median survival seen in previous trials 7 suggests that the patients in our series have not been selected for good therapy-independent prognostic factors. The increased 2-year survival rate is biologically meaningful in that patients who benefit from chemotherapy seem to have a potential for long-term survival. Although historical comparisons may not be legitimate, CCNU/TMZ almost doubled the percentage of survivors at 24 months (47,5%) compared with the EORTC/NCIC trial using TMZ monotherapy (26.5%). 1 The comparison with such historical data has to be taken with caution since MGMT promoter methylation status is not known in many of our patients (41%) and potential differences in the number of patients with methylated MGMT promoter may have a significant impact on survival data. With 16% survivors after 5 years, the rate of patients who are surviving very long and are potentially cured is also increased as compared to the rate of 4-5% that is commonly reported for glioblastoma. 8 In contrast to other studies on long-term survivors with median ages of 40.2 years 8 or 51 years 9, the long-term survivors in our study are not particularly young: the median age was 57 years (range years). Long-term survival is mainly induced by the efficient primary treatment consisting of CCNU/TMZ. Four of 7 patients surviving longer than 4 years have not relapsed so far
11 JCO/2008/ Glas et al. 10 and mpfs was longer during CCNU/TMZ therapy (mpfs 10 months) than during second-line therapy (mpfs 6 months) or further salvage therapies. However, the high rate of patients receiving a second resection (28%) or multiple salvage therapies or both might influence the overall survival to some extent. As in the UKT-03 cohort, the MGMT promoter status remains a very strong factor to predict the benefit from therapy in the whole cohort of patients treated with standard or intensified CCNU/TMZ. The median survival time of patients with a nonmethylated MGMT promoter is 12.5 months, essentially the time which is also achieved with radiotherapy alone as the first-line treatment. 1 In patients with a methylated MGMT promoter, the mos (34.5 months) is almost tripled compared to patients with a non-methylated MGMT promoter. Obviously, there is no evidence that a CCNU/TMZ-induced MGMT depletion breaks resistance to chemotherapy in MGMT-non-methylated patients. Thus, patients with a non-methylated MGMT promoter in their tumor may not take benefit from CCNU/TMZ at any dose. Consequently, future trials with combined CCNU/TMZ chemotherapy or other alkylating combination chemotherapy may be restricted to patients with a methylated MGMT promoter or should be at least stratified according to MGMT promoter methylation status. A significant dose intensification of TMZ in the CCNU/TMZ combination therapy appears to add an additonal marked survival benefit in the presence of high but tolerable toxicity. Admittedly, the group of patients with intensified CCNU/TMZ is small and conclusions are therefore limited, particularly because the MGMT promoter methylation status is not known in many of the patients. Nevertheless, PFS and OS in this group are substantially increased and the mos in the mixed group of MGMT-
12 JCO/2008/ Glas et al. 11 methylated and non-methylated patients treated with intensified CCNU/TMZ appears to be higher than the mos of the standard dose patients with a methylated MGMT promotor (41.5+ vs months). Most intriguingly, 4 of 8 patients in the intensified group are currently surviving for at least 56 months, 2 of them without recurrence. It is important to note that the excellent efficacy data in the intensified group may not be due to a selection of patients with favourable prognostic factors. The inclusion criteria were identical to the inclusion criteria of a previous large phase III trial. 1 More importantly, the median age (59.5 years) as a major prognostic factor was higher than in previous trials and close to the average age of patients with newly diagnosed glioblastoma in the general population. In conclusion, the combination of CCNU and TMZ shows very promising efficacy against newly diagnosed glioblastoma. The data presented here demonstrate an encouraging therapeutic potential but also the toxic limitations of the dose-intensified regimen in this setting. Further studies are warranted to optimize CCNU/TMZ combination chemotherapy.
13 JCO/2008/ Glas et al. 12 Table 1: Demographic data of 39 patients treated with CCNU and temozolomide Characteristic Patients (n) Patients (%) Age < 50 years 50 years Sex Male Female KPS Extent of surgery Complete resection Partial resection Biopsy NA RTOG RPA class Class III Class IV Class V Abbreviations: KPS, Karnofsky performance score; RTOG RPA, Radiation Therapy Oncology Group recursive partitioning analysis; NA, not assessable.
14 JCO/2008/ Glas et al. 13 Table 2: Univariate and multivariate Cox regression analysis for factors potentially influencing overall survival in 39 patients treated with CCNU and temozolomide Univariate analysis Median survival in months (No. of patients) Hazard ratio (lower-upper 95% CI) Condition 1 Condition 2 Condition 1 vs. 2 p* RTOG RPA class Extent of resection MGMT promoter status CCNU/TMZ dosing Multivariate analysis III 22.9 (8) Complete 27.5 (14) Methylated 34.3 (11) Intensified >41.5 (8) IV or V 24.8 (31) 1.06 ( ) 0.78 Partial or biopsy 22.6 (23) 0.89 ( ) 0.52 Nonmethylated 12.5 (12) 0.40 ( ) Standard 22.6 (31) 0.52 ( ) MGMT promoter status Methylated 34.3 Nonmethylated ( ) CCNU/TMZ dosing Intensified >41.5 (8) Standard 22.6 (31) 0.37 ( ) Abbreviations: CI, confidence interval; CCNU, lomustine; TMZ, temozolomide; MGMT, O6- methylguanine-dna methyltransferase; RTOG RPA, Radiation Therapy Oncology Group recursive partitioning analysis which integrates data on performance score, age and extent of resection; *chi-square test.
15 JCO/2008/ Glas et al. 14 Supplement 1: Salvage therapy applied to 27 patients receiving CCNU/TMZ as firstline therapy Patient OS Second-line therapy Third-line therapy Fourth-line t herapy No. Treatment PFS [m] Treatment PFS [m] Treatment PFS [m] Resection + TMZ 7/ TMZ 7/ ACNU / VM Resection + TMZ 7/7 5 Resection + TMZ 7/7 4 CCNU Resection + ACNU / VM26 1, ACNU / VM RT 2 RT + TMZ 7/7 5 Resection + ACNU Resection + TMZ 7/7 9 RT + imatinib / HU TMZ 7/ Resection+ ACNU / VM26 19 RT + imatinib / HU Resection + TMZ 7/7 6 RT Resection+ ACNU / VM RT 6 ACNU Resection + TMZ 7/7 6 imatinib / HU Hyperthermia 9 imatinib / HU 4 TMZ 7/ Resection + TMZ 7/7 7 RT ACNU / VM RT Resection + RT ACNU / VM26 8 Peg-DOX ACNU / VM RT TMZ 7/ Resection RT 6 TMZ 7/ RT TMZ 7/ Abbreviations: CCNU, lomustine; imatinib / HU, imatinib / hydroxyurea; ACNU / VM26, nimustine / teniposide; OS, overall survival in months after primary diagnosis; PFS, progression-free survival in months; Resection, tumor resection; RT, radiotherapy; TMZ 7/7, intensified temozolomide, alternating weekly regimen; Peg-Dox, pegylated liposomal doxorubicine. +censored observation.
16 JCO/2008/ Glas et al. 15 Figure legends Figure 1: Overall survival (OS) in the cohort of 39 patients receiving CCNU/TMZ combined with radiotherapy as first-line therapy for glioblastoma. Figure 2: (a) PFS and (b) OS according to the MGMT promoter methylation status in 23 evaluable patients (12 unmethylated, 11 methylated). Differences in survival between the two groups were statistically significant (logrank test; p= for PFS and p= for OS). Figure 3: (a) PFS and (b) OS according to the chemotherapy dosing. Thirty-one patients received standard dose chemotherapy (standard, CCNU 100 mg/m 2 on day 1, TMZ 100 mg/m 2 on day 2-6) and 8 patients received intensified dose chemotherapy (intensified, CCNU 110 mg/m 2 on day 1, temozolomide 150 mg/m 2 on day 2-6). Differences in survival between the two groups were statistically significant (logrank test; p=0.014 for PFS and p=0.024 for OS).
17 JCO/2008/ Glas et al. 16 References 1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: , Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24: , Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: , Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG Int J Radiat Oncol Biol Phys 40:51-55, Möllemann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113: , Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: , Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: , McLendon RE, Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 98: , Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain 130: , 2007
18
19
20
21
22
Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 19 CH-857 Zurich http://www.zora.uzh.ch Year: 29 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine
More informationConcomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
More informationUniversity of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,
More informationAn international study under the guidance of the European Organization
2617 COMMENTARY Chemotherapy for Glioblastoma Is Costly Better? Ute Linz, MD, PhD Juelich Research Center, IKP/INB, Juelich, Germany. Address for reprints: Ute Linz, MD, PhD, Forschungszentrum J ulich
More informationScottish Medicines Consortium
Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly
More information3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors
research article 213 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors Yilmaz Tezcan and Mehmet Koc Department
More informationZurich Open Repository and Archive. Procarbazine and CCNU as initial treatment in gliomatosis cerebri
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Procarbazine and CCNU as initial treatment in gliomatosis cerebri Glas, M;
More informationTemozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma
Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma Correlation With MGMT Promoter Methylation Status Alba A. Brandes, MD 1 ; Enrico Franceschi, MD 1 ; Alicia Tosoni,
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationCarmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationNewcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment
Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment Jennifer Wright Neurosurgery SSC Audit Team Jennifer Wright, Rachel Tresman, Cyril Dubois, Surash Surash,
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationPrognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2013 Prognostic or predictive value of MGMT promoter methylation in gliomas
More informationLimited role for extended maintenance temozolomide for newly diagnosed glioblastoma
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2017 Limited role for extended maintenance temozolomide for newly diagnosed
More informationElderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy
Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy Christine N Chang-Halpenny, MD; Jekwon Yeh, MD; Winston W Lien, MD
More informationBevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma
Original Article Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma Lin-Bo Cai, Juan Li, Ming-Yao Lai, Chang-Guo Shan, Zong-De Lian, Wei-Ping Hong, Jun-Jie Zhen,
More informationCNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
More informationIncidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide
405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD
More informationSurvival Analysis of Glioblastoma Multiforme
DOI:10.22034/APJCP.2018.19.9.2613 RESEARCH ARTICLE Editorial Process: Submission:04/24/2018 Acceptance:08/19/2018 Supapan Witthayanuwat, Montien Pesee*, Chunsri Supaadirek, Narudom Supakalin, Komsan Thamronganantasakul,
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationChemotherapy in malignant brain tumors
Chemotherapy in malignant brain tumors Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH 4031 Basel zimmermannf@uhbs.ch Tumor types Neuro-epithelial tumors - Glioblastoma
More informationZurich Open Repository and Archive
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Nomograms for predicting survival of patients with newly diagnosed glioblastoma:
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationConcurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme
Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme Adam J. Kole, MD, PhD 1 ; Henry S. Park, MD, MPH 1 ; Debra N. Yeboa, MD 1 ; Charles E. Rutter, MD 1 ; Christopher
More informationAdeberg et al. BMC Cancer (2015) 15:558 DOI /s x
Adeberg et al. BMC Cancer (2015) 15:558 DOI 10.1186/s12885-015-1545-x RESEARCH ARTICLE Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses
More informationDepartment of Medical Oncology, National Cancer Institute of Aviano, Aviano (PN) Italy 3
WCRJ 2014; 1 (4): e401 RADIOCHEMOTHERAPY FOR UNRESECTABLE GLIOBLASTOMA MULTIFORME: A MONO- INSTITUTIONAL EXPERIENCE M. COLELLA 1, F. FIORICA 1, P. API 1, A. STEFANELLI 1, B. URBINI 2, A. SGUALDO 1, D.
More informationHigh-grade glioma (World Health Organization Grades III and IV) Salvage Therapy in Patients with Glioblastoma. Is There any Benefit?
2678 Salvage Therapy in Patients with Glioblastoma Is There any Benefit? Peter Hau, M.D. 1 Ulrike Baumgart, M.D. 1 Katharina Pfeifer, M.D. 1 Anne Bock, R.N. 1 Tanya Jauch, R.N. 1 Jörg Dietrich, M.D. 1,2
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationDose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
J Neurooncol (2012) 108:195 200 DOI 10.1007/s11060-012-0832-5 CLINICAL STUDY Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study Walter Taal Joyce M. W. Segers-van Rijn
More informationBevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly-diagnosed glioblastoma
Bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly-diagnosed glioblastoma Design and analysis of single-arm Phase II clinical trial
More informationdoi: /bjr/
doi: 10.1259/bjr/29022270 Prognostic factors in the consecutive institutional series of glioblastoma multiforme patients who received high-dose particle radiotherapy or conventional radiotherapy Masahide
More informationSee the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, An extent of resection threshold for newly diagnosed glioblastomas
See the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, 2011 An extent of resection threshold for newly diagnosed glioblastomas Clinical article Nader Sanai, M.D., 1 Mei-Yin Polley,
More informationAdjuvant treatment of high grade gliomas
17 (Supplement 10): x186 x190, 2006 doi:10.1093/annonc/mdl258 Adjuvant treatment of high grade gliomas M. J. van den Bent Department of Neuro-Oncology, Erasmus University Hospital Rotterdam/Rotterdam Cancer
More informationDefining pseudoprogression in glioblastoma multiforme
European Journal of Neurology 2013, 20: 1335 1341 CME ARTICLE doi:10.1111/ene.12192 Defining pseudoprogression in glioblastoma multiforme E. Van Mieghem a, A. Wozniak b, Y. Geussens c, J. Menten c, S.
More informationTechnology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 NICE 2018. All rights reserved.
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationMarizomib (MRZ): Brain Penetrant Irreversible Pan-Proteasome Inhibitor
MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY Daniela Bota, MD, PhD 1, Annick Desjardins, MD,
More informationThe Response to Chemo Radiation. Therapy in Unresectable Glioblastoma
Research Article imedpub Journals http://www.imedpub.com Journal of Clinical Epigenetics DOI: 10.21767/2472-1158.100054 Abstract The Response to Chemo Radiation Therapy in Unresectable Glioblastoma Multiforme
More informationPrior to 1993, the only data available in the medical
Neuro-Oncology Prospective clinical trials of intracranial low-grade glioma in adults and children Edward G. Shaw 1 and Jeffrey H. Wisoff Department of Radiation Oncology, Wake Forest University School
More informationInterferon β and temozolomide combination therapy for temozolomide monotherapy refractory malignant gliomas
MOLECULAR AND CLINICAL ONCOLOGY 3: 909-913, 2015 Interferon β and temozolomide combination therapy for temozolomide monotherapy refractory malignant gliomas HIROSHI KAWAJI, TSUTOMU TOKUYAMA, TOMOHIRO YAMASAKI,
More informationNon-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma. Multiforme Treated with Bevacizumab
Research Article imedpub Journals www.imedpub.com Archives in Cancer Research DOI: 10.21767/2254-6081.100177 Non-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma Multiforme Treated
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationEarly postoperative tumor progression predicts clinical outcome in glioblastoma implication for clinical trials
J Neurooncol (2017) 132:249 254 DOI 10.1007/s11060-016-2362-z CLINICAL STUDY Early postoperative tumor progression predicts clinical outcome in glioblastoma implication for clinical trials Andreas Merkel
More informationManagement of Glioma: The Basics Glioma Update The clinical challenge. Glioma a malignant disease of the CNS
Management of Glioma: The Basics Glioma Update 3 oger Stupp, MD Department of Oncology & Cancer Center University Hospital Zurich, Switzerland (roger.stupp@usz.ch) Bern, 3. August 3 The clinical challenge
More informationRadioterapia no Tratamento dos Gliomas de Baixo Grau
Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic
More informationConcepts for a personalized neurosurgical oncology. XXIV Annual Conference Pietro Paoletti 27. November 2015
Concepts for a personalized neurosurgical oncology Jörg-Christian Tonn Dept. of Neurosurgery Ludwig-Maximilian University München Großhadern Germany XXIV Annual Conference Pietro Paoletti 27. November
More informationJ Clin Oncol 27: by American Society of Clinical Oncology INTRODUCTION
VOLUME 27 NUMBER 8 MARCH 10 2009 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients
More informationStephanie E. Combs Æ Marc Bischof Æ Thomas Welzel Æ Holger Hof Æ Susanne Oertel Æ Jürgen Debus Æ Daniela Schulz-Ertner
J Neurooncol (2008) 89:205 210 DOI 10.1007/s11060-008-9607-4 CLINICAL-PATIENT STUDIES Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT)
More informationSurvival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study
Original Article Research in Oncology June 2017; Vol. 13, No. 1: 18-22. DOI: 10.21608/resoncol.2017.552.1022 Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy:
More informationORIGINAL PAPERS. The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme
ORIGINAL PAPERS Adv Clin Exp Med 2015, 24, 2, 279 287 DOI: 10.17219/acem/40456 Copyright by Wroclaw Medical University ISSN 1899 5276 Anna Brzozowska 1, 2, A D, Anna Toruń 3, G, Maria Mazurkiewicz1, 2,
More informationLow grade glioma: a journey towards a cure
Editorial Page 1 of 5 Low grade glioma: a journey towards a cure Ali K. Choucair SIU School of Medicine, Springfield, IL, USA Correspondence to: Ali K. Choucair, MD. Professor of Neurology, Director of
More informationNeuro-Oncology. Martin J. van den Bent. Department of Neuro-oncology/Neurology, Erasmus M.C. Cancer Institute, Rotterdam, Netherlands
Neuro-Oncology Neuro-Oncology 16(12), 1570 1574, 2014 doi:10.1093/neuonc/nou297 Advance Access date 29 October 2014 Practice changing mature results of RTOG study 9802: another positive PCV trial makes
More informationNON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
More informationRelated Policies None
Medical Policy MP 2.04.113 BCBSA Ref. Policy: 2.04.113 Last Review: 05/30/2018 Effective Date: 05/30/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationEpidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis
Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis G. Pesce 1, A. Bordoni, F. Montanaro, R. Renella 3, A. Richetti 1, D. Boscherini 3, S. Mauri 4,
More informationTemozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience
Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience *Ehab Abdou and **Mohamed Gaafar *Department of Radiation Oncology, Faculty of Medicine, Al-Azhar University, Cairo,
More informationProton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide
J Neurooncol DOI 1.17/s11-1-2228-4 CLINIcAL STUDY Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide Masashi Mizumoto 1
More informationSurgical extent impacts the value of the established prognosticators in glioblastoma patients: a prospective translational study in Asia
Page 1 of 11 Surgical extent impacts the value of the established prognosticators in glioblastoma patients: a prospective translational study in Asia Y Wang 1,2, S Li 3, Z Zhang 1, X Chen 4, G You 1, P
More informationNeuro-Oncology Program
Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationAntiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. /
Antiangiogenic drugs in unresectable glioblastoma Dra. Carmen Balañá. / Outcome for unresectable GBM Overall survival for unresectable GBM without further treatment is: 3 months at most. Radiotherapy increases
More informationRadiation and concomitant chemotherapy for patients with glioblastoma multiforme
Chinese Journal of Cancer Review Radiation and concomitant chemotherapy for patients with glioblastoma multiforme Salvador Villà 1, Carme Balañà 2 and Sílvia Comas 1 Abstract Postoperative external beam
More informationOncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013
Oncological Management of Brain Tumours Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013 Outline General considerations of Primary Brain Tumours: epidemiology, pathology, presentation. Diagnosis
More informationGlioblastoma (GBM) is the most common and
Neuro-Oncology 12(6):595 602, 2010. doi:10.1093/neuonc/noq008 Advance Access publication February 11, 2010 NEURO-ONCOLOGY Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with
More informationTreatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study
ORIGINAL ARTICLE Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study E.R. Morgan md,* A. Norman md, K. Laing md, and M.D. Seal md ABSTRACT Purpose
More informationLynn S. Ashby 1*, Kris A. Smith 2 and Baldassarre Stea 3
Ashby et al. World Journal of Surgical Oncology (2016) 14:225 DOI 10.1186/s12957-016-0975-5 REVIEW Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide
More informationUniversity of Alberta. Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers
University of Alberta Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers by Ibrahim Alnaami A thesis submitted to the Faculty of
More informationExamining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.
Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit
More informationGlioblastoma: Current Treatment Approach 8/20/2018
Glioblastoma: Current Treatment Approach 8/20/2018 Overview What is Glioblastoma? How is it diagnosed How is it treated? Principles of Treatment Surgery, Radiation, Chemotherapy Current Standard of care
More informationGoing Past the Data for Temozolomide. J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D.
Going Past the Data for Temozolomide J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D. Departments of Medicine (JLV), Neurosurgery (JLV) and Pharmacy Practice (LRB)
More informationChanging Paradigms An Update on the Multidisciplinary Management of Malignant Glioma
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Neuro Oncology Changing Paradigms An Update on the Multidisciplinary
More informationChemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402
Chemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402 Gregory Cairncross, Meihua Wang, Edward Shaw, Berndt Scheithauer
More informationCrizotinib in addition to Radiotherapy and TMZ in newly diagnosed GBM
Crizotinib in addition to Radiotherapy and TMZ in newly diagnosed GBM Juan M Sepúlveda Sánchez Unidad Multidisciplinar de Neurooncología Hospital 12 de Octubre Madrid GEINO 1402. Phase Ib, open-label,
More informationpissn , eissn Open Access Original Article
pissn 1598-2998, eissn 25-9256 Original Article https://doi.org/1143/crt.215.473 Open Access Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationTitle: Carmustine (BCNU) for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
Author's response to reviews Title: Carmustine (BCNU) for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors Authors: Thomas P Reithmeier (thomas.reithmeier@uniklinik-freiburg.de)
More informationTemozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme
Original article Annals of Oncology 16: 1177 1184, 2005 doi:10.1093/annonc/mdi225 Published online 27 April 2005 Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationPrognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status.
Prognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status. R. Zalazar, M.D. Hernández, M. Páramo, P. Slon, M. Millor Muruzabal, J. Solorzano
More informationImproved Survival after Gross Total Resection of Malignant Gliomas in Pediatric Patients from the HIT-GBM Studies
Improved Survival after Gross Total Resection of Malignant Gliomas in Pediatric Patients from the HIT-GBM Studies CHRISTOF M. KRAMM 1, SABINE WAGNER 2, STEFAN VAN GOOL 3, HANSJÖRG SCHMID 4, RONALD STRÄTER
More informationNCT HEIDELBERG NATIONAL CENTER FOR TUMOR DISEASES. Sao Paulo, Can immunotherapy be the new weapon in the treatment of gliomas?
NATIONAL CENTER FOR TUMOR DISEASES NCT HEIDELBERG Sao Paulo, 28.04.2017 Can immunotherapy be the new weapon in the treatment of gliomas? Wolfgang Wick Neurology Clinic, University of Heidelberg Neurooncology
More informationA Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM)
A Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM) Morten Mau-Sorensen 1, Scott Plotkin 2, Patrick Wen 3, Andrew
More informationThis study was designed to evaluate an online prognosis
Neuro-Oncology 15(8):1074 1078, 2013. doi:10.1093/neuonc/not033 Advance Access publication March 29, 2013 NEURO-ONCOLOGY Can the prognosis of individual patients with glioblastoma be predicted using an
More informationCitation Pediatrics international (2015), 57.
Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation
More informationBevacizumab and dose-intense temozolomide in recurrent high-grade glioma
Annals of Oncology 21: 1723 1727, 2010 doi:10.1093/annonc/mdp591 Published online 11 January 2010 Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma J. J. C. Verhoeff 1, C. Lavini
More informationNCCP Chemotherapy Regimen. Temozolomide with Radiotherapy (RT) and Adjuvant Therapy
Temozolomide with Radiotherapy (RT) INDICATIONS FOR USE: Regimen Code ISMO Contributor: Prof Maccon Keane Page 1 of 6 *Reimbursement Status INDICATION ICD10 Adult patients with newly-diagnosed glioblastoma
More informationClinical Study Hypofractionated High-Dose Irradiation with Positron Emission Tomography Data for the Treatment of Glioblastoma Multiforme
BioMed Research International Volume 14, Article ID 26, 9 pages http://dx.doi.org/.1155/14/26 Clinical Study Hypofractionated High-Dose Irradiation with Positron Emission Tomography Data for the Treatment
More informationPRESURGICAL PLANNING. Strongly consider neuropsychological evaluation before functional imaging study Strongly consider functional imaging study
NOTE: Consider Clinical Trials as treatment options for eligible patients. Page 1 of 6 RADIOLOGICAL PRESENTATION PRESURGICAL PLANNING TREATMENT Imaging study suggestive of glioma 1 Left hemisphere speech/motor
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationHematologic Toxicity of Temozolomide and Radiation in Glioblastoma Patients Correlation with Clinicopathological Factors
Clinical Medicine Journal Vol. 1, No. 2, 2015, pp. 63-69 http://www.aiscience.org/journal/cmj Hematologic Toxicity of Temozolomide and Radiation in Glioblastoma Patients Correlation with Clinicopathological
More informationORE Open Research Exeter
ORE Open Research Exeter TITLE Temozolomide for high grade glioma AUTHORS Hart, MG; Garside, R; Rogers, G; et al. JOURNAL Cochrane Database Of Systematic Reviews DEPOSITED IN ORE 22 October 2013 This version
More informationCHMP Type II variation assessment report
26 January 2017 EMA/CHMP/59238/2017 Invented name: Avastin International non-proprietary name: bevacizumab Procedure No. EMEA/H/C/000582/II/0093 Marketing authorisation holder (MAH): Roche Registration
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationRINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA
RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA MULTIFORM GEINO 2014 Dra Estela Pineda Madrid Hospital Clínic Barcelona EGFRvIII in glioblastoma multiform The most common mutation of EGFR in GBM Expressed in 30%
More informationJ Clin Oncol 26: by American Society of Clinical Oncology
VOLUME 26 NUMBER 13 MAY 1 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy
More informationData recently reported in the randomized EORTC
Neuro-Oncology 12(3):283 288, 2010. doi:10.1093/neuonc/nop050 Advance Access publication February 1, 2010 NEURO-ONCOLOGY O 6 -methylguanine DNA-methyltransferase methylation status can change between first
More information